Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialAlexander M.M. Eggermont, Ulrich Keilholz, Stefan Suciu et al.|The Lancet|2008Cited by 642
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III MelanomaAlexander M.M. Eggermont, Ulrich Keilholz, Alessandro Testori et al.|Journal of Clinical Oncology|2012Cited by 281
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic MelanomaWim H.J. Kruit, Ulrich Keilholz, Stefan Suciu et al.|Journal of Clinical Oncology|2013Cited by 222
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)Poulam M. Patel, Alan Spatz, Stefan Suciu et al.|European Journal of Cancer|2011Cited by 210
Spatially mapping the immune landscape of melanoma using imaging mass cytometryDan Moldoveanu, Ian R. Watson, LeeAnn Ramsay et al.|Science Immunology|2022Cited by 131